These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38914855)

  • 1. Disorganization in individuals at clinical high risk for psychosis: psychopathology and treatment response.
    Biancalani A; Occhionero M; Leuci E; Quattrone E; Azzali S; Paulillo G; Pupo S; Pellegrini P; Menchetti M; Pelizza L
    Eur Arch Psychiatry Clin Neurosci; 2024 Jun; ():. PubMed ID: 38914855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examining disorganization in patients with first episode psychosis: Findings from a 1-year follow-up of the 'Parma early psychosis' program.
    Pelizza L; Leuci E; Maestri D; Quattrone E; Azzali S; Paulillo G; Pellegrini P
    Early Interv Psychiatry; 2022 May; 16(5):552-560. PubMed ID: 34279049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disorganization in first episode schizophrenia: Treatment response and psychopathological findings from the 2-year follow-up of the "Parma Early Psychosis" program.
    Pelizza L; Leuci E; Maestri D; Quattrone E; Azzali S; Paulillo G; Pellegrini P; Raballo A
    J Psychiatr Res; 2021 Sep; 141():293-300. PubMed ID: 34274840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disorganization in first episode affective psychosis: Treatment response and clinical considerations from a 2-year follow-up study in a "real world" setting.
    Pelizza L; Leuci E; Maestri D; Quattrone E; Azzali S; Paulillo G; Pellegrini P
    Span J Psychiatry Ment Health; 2023; 16(3):151-158. PubMed ID: 38520114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative symptoms in first episode schizophrenia: treatment response across the 2-year follow-up of the "Parma Early Psychosis" program.
    Pelizza L; Leuci E; Maestri D; Quattrone E; Azzali S; Paulillo G; Pellegrini P
    Eur Arch Psychiatry Clin Neurosci; 2022 Jun; 272(4):621-632. PubMed ID: 35088121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline antipsychotic prescription and short-term outcome indicators in individuals at clinical high-risk for psychosis: Findings from the Parma At-Risk Mental States (PARMS) program.
    Pelizza L; Leuci E; Quattrone E; Azzali S; Paulillo G; Pupo S; Poletti M; Raballo A; Pellegrini P; Menchetti M
    Early Interv Psychiatry; 2024 Feb; 18(2):71-81. PubMed ID: 37194411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anxious-depressive symptoms after a first episode of schizophrenia: Response to treatment and psychopathological considerations from the 2-year "Parma Early Psychosis" program.
    Pelizza L; Quattrone E; Leuci E; Paulillo G; Azzali S; Pupo S; Pellegrini P
    Psychiatry Res; 2022 Nov; 317():114887. PubMed ID: 36219900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subgroups of Clinical High Risk for Psychosis Based on Baseline Antipsychotic Exposure: Clinical and Outcome Comparisons Across a 2-Year Follow-up Period.
    Pelizza L; Di Lisi A; Leuci E; Quattrone E; Azzali S; Pupo S; Paulillo G; Pellegrini P; Menchetti M
    Schizophr Bull; 2024 Mar; ():. PubMed ID: 38551332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical high risk for psychosis and service disengagement: Incidence and predictors across 2 years of follow-up.
    Catalano F; Leuci E; Quattrone E; Palmisano D; Pellegrini P; Pupo S; Menchetti M; Pelizza L
    Early Interv Psychiatry; 2024 Jul; ():. PubMed ID: 39034609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term functional outcome in psychotic patients: results of the Turku early psychosis study (TEPS).
    Salokangas RKR; From T; Ilonen T; Luutonen S; Heinimaa M; Armio RL; Laurikainen H; Walta M; Paju J; Toivonen A; Jalo P; Tuominen L; Hietala J
    BMC Psychiatry; 2021 Dec; 21(1):602. PubMed ID: 34856968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis.
    Modinos G; Kempton MJ; Tognin S; Calem M; Porffy L; Antoniades M; Mason A; Azis M; Allen P; Nelson B; McGorry P; Pantelis C; Riecher-Rössler A; Borgwardt S; Bressan R; Barrantes-Vidal N; Krebs MO; Nordentoft M; Glenthøj B; Ruhrmann S; Sachs G; Rutten B; van Os J; de Haan L; Velthorst E; van der Gaag M; Valmaggia LR; McGuire P;
    JAMA Psychiatry; 2020 Feb; 77(2):190-200. PubMed ID: 31722018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between case management and longitudinal decrease in negative symptoms in patients with first episode psychosis: A 2-year follow-up.
    Pelizza L; Maestri D; Leuci E; Quattrone E; Azzali S; Paulillo G; Pellegrini P
    Early Interv Psychiatry; 2022 Nov; 16(11):1185-1191. PubMed ID: 35086160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal persistence of negative symptoms in young individuals with first episode schizophrenia: a 24-month multi-modal program follow-up.
    Pelizza L; Leuci E; Maestri D; Quattrone E; Azzali S; Paulillo G; Pellegrini P
    Nord J Psychiatry; 2022 Oct; 76(7):530-538. PubMed ID: 34936855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mismatch Negativity in Response to Auditory Deviance and Risk for Future Psychosis in Youth at Clinical High Risk for Psychosis.
    Hamilton HK; Roach BJ; Bachman PM; Belger A; Carrión RE; Duncan E; Johannesen JK; Light GA; Niznikiewicz MA; Addington J; Bearden CE; Cadenhead KS; Cornblatt BA; McGlashan TH; Perkins DO; Tsuang MT; Walker EF; Woods SW; Cannon TD; Mathalon DH
    JAMA Psychiatry; 2022 Aug; 79(8):780-789. PubMed ID: 35675082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent negative symptoms in young people at clinical high risk of psychosis treated with an Italian early intervention program: a longitudinal study.
    Ricci C; Leuci E; Quattrone E; Palmisano D; Pellegrini P; Menchetti M; Pupo S; Pelizza L
    Eur Arch Psychiatry Clin Neurosci; 2024 Sep; 274(6):1311-1326. PubMed ID: 38668766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between symptom and neurocognitive dimensions in clinical high risk for psychosis.
    Aase I; Langeveld JH; Joa I; Johannessen JO; Dalen I; Ten Velden Hegelstad W
    Schizophr Res Cogn; 2022 Sep; 29():100260. PubMed ID: 35677653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms.
    Healy C; Byrne J; Raj Suasi S; Föcking M; Mongan D; Kodosaki E; Heurich M; Cagney G; Wynne K; Bearden CE; Woods SW; Cornblatt B; Mathalon D; Stone W; Cannon TD; Addington J; Cadenhead KS; Perkins D; Jeffries C; Cotter D
    Brain Behav Immun; 2024 Mar; 117():175-180. PubMed ID: 38219978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Pre-onset Subthreshold Psychotic Symptoms With Longitudinal Outcomes During Treatment of a First Episode of Psychosis.
    Rosengard RJ; Malla A; Mustafa S; Iyer SN; Joober R; Bodnar M; Lepage M; Shah JL
    JAMA Psychiatry; 2019 Jan; 76(1):61-70. PubMed ID: 30304442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Duration of untreated psychosis: A state-of-the-art review and critical analysis].
    Souaiby L; Gaillard R; Krebs MO
    Encephale; 2016 Aug; 42(4):361-6. PubMed ID: 27161262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsychotic Exposure in Clinical High Risk of Psychosis: Empirical Insights From a Large Cohort Study.
    Zeng J; Raballo A; Gan R; Wu G; Wei Y; Xu L; Tang X; Hu Y; Tang Y; Chen T; Li C; Wang J; Zhang T
    J Clin Psychiatry; 2022 Mar; 83(3):. PubMed ID: 35324095
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.